WallStreetZenWallStreetZen

NASDAQ: VERA
Vera Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VERA

Based on 6 analysts offering 12 month price targets for Vera Therapeutics Inc

Min Forecast
$70.00+89.24%
Avg Forecast
$88.00+137.9%
Max Forecast
$125.00+237.93%

Should I buy or sell VERA stock?

Based on 6 analysts offering ratings for Vera Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
3 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VERA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VERA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their VERA stock forecasts and price targets.

VERA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-08
lockedlocked$00.00+00.00%2026-07-08Find Out Why
lockedlocked$00.00+00.00%2026-07-08
lockedlocked$00.00+00.00%2026-07-07
lockedlocked$00.00+00.00%2026-05-15
Wolfe Research
Top 15%
86
BuyUpgrades$88.00+137.90%2026-03-11

1 of 1

Forecast return on equity

Is VERA forecast to generate an efficient return?

Company
66.34%
Industry
90.27%
Market
172.07%
VERA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERA forecast to generate an efficient return on assets?

Company
53.32%
Industry
27.3%
VERA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERA earnings per share forecast

What is VERA's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$6.24
Avg 2 year Forecast
-$3.81
Avg 3 year Forecast
$0.10

VERA revenue forecast

What is VERA's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$36.3M
Avg 2 year Forecast
$266.3M
Avg 3 year Forecast
$726.9M

VERA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERA$36.99$88.00+137.90%Strong Buy
ATAI$7.19$10.83+50.67%Buy
BEAM$26.33$57.00+116.48%Strong Buy
KOD$40.87$66.33+62.30%Strong Buy
CLDX$35.42$55.86+57.70%Strong Buy
View Top Biotech Stocks

Vera Therapeutics Stock Forecast FAQ

Is Vera Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: VERA) stock is to Strong Buy VERA stock.

Out of 6 analysts, 3 (50%) are recommending VERA as a Strong Buy, 3 (50%) are recommending VERA as a Buy, 0 (0%) are recommending VERA as a Hold, 0 (0%) are recommending VERA as a Sell, and 0 (0%) are recommending VERA as a Strong Sell.

If you're new to stock investing, here's how to buy Vera Therapeutics stock.

What is VERA's earnings growth forecast for 2026-2028?

(NASDAQ: VERA) Vera Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.

Vera Therapeutics's earnings in 2026 is -$368,953,000.On average, 14 Wall Street analysts forecast VERA's earnings for 2026 to be -$447,796,112, with the lowest VERA earnings forecast at -$465,067,078, and the highest VERA earnings forecast at -$419,068,594. On average, 14 Wall Street analysts forecast VERA's earnings for 2027 to be -$273,607,717, with the lowest VERA earnings forecast at -$342,734,653, and the highest VERA earnings forecast at -$156,773,862.

In 2028, VERA is forecast to generate $6,912,694 in earnings, with the lowest earnings forecast at -$165,316,028 and the highest earnings forecast at $274,354,259.

What is VERA's revenue growth forecast for 2026-2028?

(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.

Vera Therapeutics's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast VERA's revenue for 2026 to be $2,606,078,330, with the lowest VERA revenue forecast at $844,166,951, and the highest VERA revenue forecast at $5,548,028,867. On average, 13 Wall Street analysts forecast VERA's revenue for 2027 to be $19,117,940,822, with the lowest VERA revenue forecast at $9,145,141,970, and the highest VERA revenue forecast at $34,861,367,328.

In 2028, VERA is forecast to generate $52,175,403,772 in revenue, with the lowest revenue forecast at $33,422,120,102 and the highest revenue forecast at $93,533,123,912.

What is VERA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VERA) forecast ROA is 53.32%, which is higher than the forecast US Biotechnology industry average of 27.3%.

What is VERA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year VERA price target, the average VERA price target is $88.00, with the highest VERA stock price forecast at $125.00 and the lowest VERA stock price forecast at $70.00.

On average, Wall Street analysts predict that Vera Therapeutics's share price could reach $88.00 by Jul 8, 2027. The average Vera Therapeutics stock price prediction forecasts a potential upside of 137.9% from the current VERA share price of $36.99.

What is VERA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VERA) Vera Therapeutics's current Earnings Per Share (EPS) is -$5.54. On average, analysts forecast that VERA's EPS will be -$6.24 for 2026, with the lowest EPS forecast at -$6.48, and the highest EPS forecast at -$5.84. On average, analysts forecast that VERA's EPS will be -$3.81 for 2027, with the lowest EPS forecast at -$4.77, and the highest EPS forecast at -$2.18. In 2028, VERA's EPS is forecast to hit $0.10 (min: -$2.30, max: $3.82).

What is VERA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VERA) forecast ROE is 66.34%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.